 |
 |
It appears that other newspapers and online news sites have picked up the New York Times article " Many See Hope in Parkinson's Drug Pulled From Testing" by Andrew Pollack, and some have edited it down in length. The NY Times version is the best. Other articles on the halted GDNF trial and the plight of the patient subjects have also appeared in Newsday, and Bristol (U.K.) papers, and have also been posted on PIEN. The Parkinson's Pipeline Project, a grassroots organization of PWP, who are working together to help accelerate the production of safe, effective, and timely new treatments for Parkinson's have written a letter to Amgen about the halt of their GDNF trial and their denial of continued treatment for the trial subjects. Many questions remain unanswered. You can read the letter at: http://www.pdpipeline.org/amgen_letter-112004.htm We encourage other PD groups and individuals to contact Amgen as well. Letters can be addressed to: Kevin Sharer Chairman of the Board, Chief Executive Officer and President Dr. Roger M. Perlmutter Executive Vice President, Research and Development Dr.Joseph Miletich Senior Vice President, Research and Pre-clinical Development Amgen Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799 If you do write to Amgen, please send a copy of your letter to the Parkinson's Pipeline Project at [log in to unmask] Thanks, Linda ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn